About

BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. BrightEdge propels groundbreaking patient-centric solutions by accelerating ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.

About

BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. BrightEdge propels groundbreaking patient-centric solutions by accelerating ACS’s mission to advance science, reducing disparities, and promoting healthcare sustainability.

Our Mission

Leading the fight for a world without cancer.
BrightEdge operates at the intersection of impact, innovation, and investment to accelerate the American Cancer Society’s goal to reduce cancer mortality. The BrightEdge investment team utilizes a unique and proprietary Cancer Impact Investment Framework™ (“CIIF”) to assess and due diligence investments and opportunities.
Our Connection
BrightEdge leverages ACS’s unparalleled knowledge base to catalyze impact innovation by strategically investing in entrepreneurial early-stage companies
American Cancer Society Logo

$5.0b+

Invested in Research Since 1946

49

Nobel Laureates

31%

Decline in Mortality Rate Since 1991

Investing for Real Impact

BrightEdge invests for and drives ACS mission through high-quality deals and patient-centric innovation and generates market-rate returns • Financial returns realized from investments are reinvested and/or returned to ACS, building a diversified and sustainable source of funding for the ACS’s life-saving body of work. • Donations to BrightEdge will become a sustainable source of financial support for the American Cancer Society to provide needed services locally to people facing cancer today and tomorrow in more than 5,000 communities. • Investment returns from the BrightEdge portfolio are both reinvested in BrightEdge and used to sustain American Cancer Society’s life-saving programs in research, access, and health equity.

BrightEdge Portfolio Companies are...

  • Attacking Cancer

    Propelling groundbreaking patient-centric solutions to accelerate the ACS’s mission to advance science, reduce disparities, and promote healthcare sustainability.

  • Focused on Health Equity

    Seeking to broaden and accelerate patient access to life-saving innovations by developing technology-enabled solutions that will transform the way healthcare is delivered and experienced.

  • In All Stages of Development

    Today, our ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate ACS’s mission of ending cancer as we know it, for everyone. 

  • Funded by Industry-Leading VCs

    BrightEdge invests alongside the industry’s top VC funds to accelerate the most innovative companies that are raising capital through equity or convertible debt. (Note that while ACS Research distributes over one hundred million dollars of translational grants per year, BrightEdge does not provide grant funding.) BrightEdge plays a unique role by bringing system-level knowledge to early-stage companies at critical points in product strategy and helps portfolio companies access world-class intellectual and human capital as they grow.